FENC
Fennec Pharmaceuticals Inc.
$7.94
+$0.10(+1.28%)
38
Overall
40
Value
36
Tech
--
Quality
Market Cap
$236.01M
Volume
192.64K
52W Range
$3.96 - $9.92
Target Price
$14.00
Company Overview
| Mkt Cap | $236.01M | Price | $7.94 |
| Volume | 192.64K | Change | +1.28% |
| P/E Ratio | -- | Open | $7.80 |
| Revenue | -- | Prev Close | $7.84 |
| Net Income | -- | 52W Range | $3.96 - $9.92 |
| Div Yield | N/A | Target | $14.00 |
| Overall | 38 | Value | 40 |
| Quality | -- | Technical | 36 |
No chart data available
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Boston Scientific (BSX)
Christine Brown•2 days ago
Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position
TipRanks Canadian Auto-Generated Newsdesk•3 days ago
Fennec Pharmaceuticals Reports Increased PEDMARK Sales
TipRanks Auto-Generated Newsdesk•4 days ago
Wedbush Remains a Buy on Fennec Pharmaceuticals (FENC)
TipRanks Auto-Generated Intelligence Newsdesk•8 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FENC | $7.94 | +1.3% | 192.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fennec Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW